Cisplatin for small cell lung cancer: Associated publications in Science Citation Index Expanded

Ho,Yuh‑Shan; Nakazawa,Kensuke; Sato,Shinya; Tamura,Tomohiro; Kurishima,Koichi; Satoh,Hiroaki

doi:10.3892/ol.2012.1029

Cisplatin for small cell lung cancer: Associated publications in Science Citation Index Expanded

Authors:
- Yuh‑Shan Ho
- Kensuke Nakazawa
- Shinya Sato
- Tomohiro Tamura
- Koichi Kurishima
- Hiroaki Satoh
View Affiliations

Affiliations: Trend Research Centre, Asia University, Taichung 41354, Taiwan, Division of Respiratory Medicine, Institute of Clinical Medicine, University of Tsukuba, Tsukuba, Ibaraki 305‑8575, Japan, Division of Respiratory Medicine, Mito Medical Center, University of Tsukuba, Mito, Ibaraki 310‑0015, Japan
Published online on: November 15, 2012 https://doi.org/10.3892/ol.2012.1029
Pages: 684-688

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

This study was conducted to explore a bibliometric approach to quantitatively assess current research trends in cisplatin‑containing chemotherapy for small cell lung cancer (SCLC), using related literature in the Science Citation Index Expanded database from 1992 to 2011. Articles were analyzed by the scientific output and research performances of countries and institutions. The distribution of key words in the article title and author‑selected keywords were used to evaluate research trends. It was observed that the number of articles devoted to cisplatin‑containing chemotherapy for SCLC did not increase with time. The USA and Japan were the top two countries with the highest number of articles devoted to cisplatin‑containing chemotherapy for SCLC. In both countries, the number of articles did not increase with time, and a decreasing trend was identified in the USA over the last 10 years. This study demonstrates trends in cisplatin‑containing chemotherapy for SCLC. The clinical application of novel drugs is required for successful SCLC treatment.

View Figures

View References

1.	Youlden DR, Cramb SM and Baade PD: The international epidemiology of lung cancer: geographical distribution and secular trends. J Thorac Oncol. 3:819–831. 2011. View Article : Google Scholar : PubMed/NCBI
2.	Ferraldeschi R, Baka S, Jyoti B, et al: Modern management of small-cell lung cancer. Drugs. 67:2135–2152. 2007. View Article : Google Scholar : PubMed/NCBI
3.	Simon GR and Turrisi A; American College of Chest Physicians: Management of small cell lung cancer: ACCP evidence-based clinical practice guidelines (2nd edition). Chest. 132(Suppl 3): 324S–339S. 2007. View Article : Google Scholar : PubMed/NCBI
4.	Sangha R, Lara PN Jr, Adjei AA, et al: Cooperative group research endeavors in small-cell lung cancer: current and future directions. Clin Lung Cancer. 10:322–330. 2009. View Article : Google Scholar : PubMed/NCBI
5.	Planchard D and Le Péchoux C: Small cell lung cancer: new clinical recommendations and current status of biomarker assessment. Eur J Cancer. 47(Suppl 3): S272–S283. 2011. View Article : Google Scholar : PubMed/NCBI
6.	Abrams TJ, Lee LB, Murray LJ, et al: SU11248 inhibits KIT and platelet-derived growth factor receptor beta in preclinical models of human small cell lung cancer. Mol Cancer Ther. 2:471–478. 2003.PubMed/NCBI
7.	Sher T, Dy GK and Adjei AA: Small cell lung cancer. Mayo Clin Proc. 83:355–367. 2008. View Article : Google Scholar
8.	Chen G, Huynh M, Fehrenbacher L, et al: Phase II trial of irinotecan and carboplatin for extensive or relapsed small-cell lung cancer. J Clin Oncol. 27:1401–1404. 2009. View Article : Google Scholar : PubMed/NCBI
9.	Go RS and Adjei AA: Review of the comparative pharmacology and clinical activity of cisplatin and carboplatin. J Clin Oncol. 17:409–422. 1999.PubMed/NCBI
10.	Iwasaki Y, Nagata K, Nakanishi M, et al: Double-cycle, high-dose ifosfamide, carboplatin, and etoposide followed by peripheral blood stem-cell transplantation for small cell lung cancer. Chest. 128:2268–2273. 2005. View Article : Google Scholar : PubMed/NCBI
11.	Kosmas C, Tsavaris NB, Malamos NA, et al: Phase II study of paclitaxel, ifosfamide, and cisplatin as second-line treatment in relapsed small-cell lung cancer. J Clin Oncol. 19:119–126. 2001.PubMed/NCBI
12.	Spiro SG, Tanner NT, Silvestri GA, et al: Lung cancer: progress in diagnosis, staging and therapy. Respirology. 15:44–50. 2010. View Article : Google Scholar : PubMed/NCBI
13.	Mela GS, Cimmino MA and Ugolini D: Impact assessment of oncology research in the European Union. Eur J Cancer. 35:1182–1186. 1999. View Article : Google Scholar : PubMed/NCBI
14.	Li WT and Yang YN: Zipf’s law in importance of genes for cancer classification using microarray data. J Theor Biol. 219:539–551. 2002.
15.	Grossi F, Belvedere O and Rosso R: Geography of clinical cancer research publications from 1995 to 1999. Eur J Cancer. 39:106–111. 2003. View Article : Google Scholar : PubMed/NCBI
16.	Cimmino MA, Maio T, Ugolini D, et al: Trends in otolaryngology research during the period 1995–2000: a bibliometric approach. Otolaryngol Head Neck Surg. 132:295–302. 2005.
17.	Cambrosio A, Keating P, Mercier S, et al: Mapping the emergence and development of translational cancer research. Eur J Cancer. 42:3140–3148. 2006. View Article : Google Scholar : PubMed/NCBI
18.	Bingley AF, McDermott E, Thomas C, et al: Making sense of dying: a review of narratives written since 1950 by people facing death from cancer and other diseases. Palliat Med. 20:183–195. 2006. View Article : Google Scholar : PubMed/NCBI
19.	Rada R: Characterizing cancer information systems. J Med Syst. 30:153–157. 2006. View Article : Google Scholar : PubMed/NCBI
20.	Ugolini D, Puntoni R, Perera FP, et al: A bibliometric analysis of scientific production in cancer molecular epidemiology. Carcinogenesis. 28:1774–1779. 2007. View Article : Google Scholar : PubMed/NCBI
21.	Klar M, Földi M, Denschlag D, et al: Estimates of global research productivity in gynecologic oncology. Int J Gynecol Cancer. 19:489–493. 2009. View Article : Google Scholar : PubMed/NCBI
22.	Glynn RW, Scutaru C, Kerin MJ, et al: Breast cancer research output, 1945–2008: a bibliometric and density-equalizing analysis. Breast Cancer Res. 12:R1082010.
23.	Ugolini D, Neri M, Casilli C, et al: A bibliometric analysis of scientific production in mesothelioma research. Lung Cancer. 70:129–135. 2010. View Article : Google Scholar : PubMed/NCBI
24.	Ho YS, Satoh H and Lin SY: Japanese lung cancer research trends and performance in Science Citation Index. Intern Med. 49:2219–2228. 2010. View Article : Google Scholar : PubMed/NCBI
25.	Lewison G, Purushotham A, Mason M, et al: Understanding the impact of public policy on cancer research: A bibliometric approach. Eur J Cancer. 46:912–919. 2010. View Article : Google Scholar : PubMed/NCBI
26.	Suk FM, Lien GS, Yu TC and Ho YS: Global trends in Helicobacter pylori research from 1991 to 2008 analyzed with the Science Citation Index Expanded. Eur J Gastroenterol Hepatol. 23:295–301. 2011.
27.	Lin HW, Yu TC and Ho YS: A systemic review of human papillomavirus studies: global publication comparison and research trend analyses from 1993 to 2008. Eur J Gynaecol Oncol. 32:133–140. 2011.PubMed/NCBI
28.	Micheli A, Di Salvo F, Lombardo C, et al: Cancer research performance in the European Union: a study of published output from 2000 to 2008. Tumori. 97:683–689. 2011.PubMed/NCBI
29.	Li LL, Ding G, Feng N, et al: Global stem cell research trend: bibliometric analysis as a tool for mapping of trends from 1991 to 2006. Scientometrics. 80:39–58. 2009. View Article : Google Scholar
30.	Mao N, Wang MH and Ho YS: A bibliometric study of the trend in articles related to risk assessment published in Science Citation Index. Human Ecol Risk Assess. 16:801–824. 2010. View Article : Google Scholar
31.	Zhang GF, Xie SD and Ho YS: A bibliometric analysis of world volatile organic compounds research trends. Scientometrics. 83:477–492. 2010. View Article : Google Scholar
32.	Li T, Ho YS and Li CY: Bibliometric analysis on global Parkinson’s disease research trends during 1991–2006. Neurosci Lett. 441:248–252. 2008.
33.	Chen SR, Chiu WT and Ho YS: Asthma in children: mapping the literature by bibliometric analysis. Rev Fr Immunol Clin. 45:442–446. 2005.
34.	Han JS and Ho YS: Global trends and performances of acupuncture research. Neurosci Biobehav Rev. 35:680–687. 2011. View Article : Google Scholar : PubMed/NCBI
35.	Malarvizhi R, Wang MH and Ho YS: Research trends in adsorption technologies for dye containing wastewaters. W Appl Sci J. 8:930–942. 2010.
36.	Bhandari M, Busse JW, Kulkarni AV, et al: Interpreting authorship order and corresponding authorship. Epidemiol. 15:125–126. 2004. View Article : Google Scholar : PubMed/NCBI
37.	Burman KD: ‘Hanging from the masthead’: reflections on authorship. Ann Intern Med. 97:602–605. 1982.
38.	Crystal AS and Shaw AT: New targets in advanced NSCLC: EML4-ALK. Clin Adv Hematol Oncol. 9:207–214. 2011.PubMed/NCBI
39.	Schmittel A: Second-line therapy for small-cell lung cancer. Exp Rev of Anticancer Ther. 11:631–637. 2011. View Article : Google Scholar : PubMed/NCBI
40.	Jotte R, Conkling P, Reynolds C, et al: Randomized phase II trial of single-agent amrubicin or topotecan as second-line treatment in patients with small-cell lung cancer sensitive to first-line platinum-based chemotherapy. J Clin Oncol. 29:287–293. 2011. View Article : Google Scholar : PubMed/NCBI